Mereo BioPharma
MREO
86 hedge funds and large institutions have $268M invested in Mereo BioPharma in 2025 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 16 closing their positions.
148% more call options, than puts
Call options by funds: $8.29M | Put options by funds: $3.35M
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
48.13% more ownership
Funds ownership: 13.97% → 62.11% (+48%)
7% more capital invested
Capital invested by funds: $250M → $268M (+$17.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 90 → 86 (-4)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$3.91M |
| 2 |
Goldman Sachs
New York
|
+$2.33M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$2.03M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.74M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$12.2M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$5.36M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.83M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$3.53M |
| 5 |
Morgan Stanley
New York
|
-$3.36M |
MREO Hedge Fund Activity: Q2 2025 in Review
86 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2025, worth a combined $268M — up 7% from $250M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of MREO and 12 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 31 added.
The largest buyer was Frazier Life Sciences Management, adding an estimated $3.91M. The largest seller was Janus Henderson Group, cutting an estimated $12.2M.
- 86 institutional investors held Mereo BioPharma (MREO) as of Q2 2025, down from 90 in Q1 2025.
- Funds reported $268M of Mereo BioPharma stock for Q2 2025, up 7% quarter-over-quarter.
- 12 funds opened new Mereo BioPharma positions in Q2 2025 and 16 closed out, a net change of -4 holders.
- The largest Mereo BioPharma buyer in Q2 2025 was Frazier Life Sciences Management, an estimated $3.91M added.
- The largest Mereo BioPharma seller in Q2 2025 was Janus Henderson Group, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2025.